Nora m chapman editor (1 risultati)
- Rilegato
- Prima edizione
Da: killarneybooks, Inagh, CLARE, Irlandakillarneybooks
Contatta il venditoreVenditore con 5 stelleCondizione: Usato - Buono
EUR 22,61
EUR 33,70 spedizioneSpedito da Irlanda a U.S.A.Quantità: 1 disponibili
Hardcover. Condizione: Good. 1st Edition. Hardcover, x + 311pp, subject index. Not an Indian economy edition, printed in Germany. Ex-university library, marked "discard". An external stamp on all outer page edges, internal library markings: a stamped bookplate inside front cover, pencil inventory numbers on the reverse of tile p…age, two narrow partially removed labels below the upper edge of rear endpapers (non-sticky glue residue and small areas of superficial sticker damage). Interior is gently age-toned, clean, with unmarked text and good secure binding. Short creases to tips of lower page corners throughout the book. Boards show gentle shelfwear, short creases to corners, some tiny indentations to edges; a short, superficial edge-nick to the tip of lower outer corner of front panel. Published without a dust jacket. -- Late in the 1940s, a virus was isolated from a young patient with a flaccid paralysis in the sleepy Hudson River town of Coxsackie in the state of New York. Within the next few years, it was apparent that this and other similar viruses were not polioviruses but were indeed a new group of viruses, viruses that by the mid-1950s had been found to be commonly associated with pediatric inflammatory heart disease. Two groups of coxsackie viruses (A and B) were differentiated on the basis of the type of paralysis induced in suckling mice by these viruses. Group B coxsackieviruses, because of their primacy as etiologic agents of human acute viral myocarditis and its relatively common sequela, dilated cardiomyopathy, are the focus of this volume. As the end of the century approaches, the massive international effort to eradicate polioviruses through vaccination as causes of human disease has been successful in the Western Hemisphere and in many parts of Europe, and it is expected that worldwide eradication may be achieved within the near future. While this is wonderful news, there are sadly no similar efforts being planned to combat the numerous other human enteroviruses that daily incur widespread morbidity and mortality throughout the world. While this is due in part to the lack of specific knowledge about the other human enteroviruses, it is also due to the perceptions of industry that there is insufficient profit to be made by developing these vaccines.
